Penny stocks can offer high risk and high reward opportunities for investors. Hoth Therapeutics, valued at $18.4 million, is a clinical-stage biopharmaceutical company with a diverse pipeline and promising clinical programs. Wall Street analysts have given HOTH a “Strong Buy” rating with a potential 262.3% gain in the next 12 months. On the other hand, Arcturus Therapeutics, valued at $287.8 million, is focused on RNA delivery technologies for rare diseases and vaccines. ARCT stock has seen a 41.4% YTD decrease but has a “Strong Buy” rating with a potential 1,222% gain over the next 12 months according to analysts.

Read more at Barchart.: 2 Stocks to Buy Under $10 That Wall Street Loves